Amundi
SRPT icon

Amundi’s Sarepta Therapeutics SRPT Stock Holding History

Amundi’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Buy
+19,456
New +$368K ﹤0.01% 1792
2026
Q1 		– Sell
-10,257
Closed -$221K – 2089
2025
Q4 		$221K Sell
10,257
-959,569
-99% -$20.2M ﹤0.01% 1731
2025
Q3 		$22.6M Buy
969,826
+767,026
+378% +$13.7M 0.01% 713
2025
Q2 		$3.69M Sell
202,800
-253,989
-56% -$10.8M ﹤0.01% 977
2025
Q1 		$26.8M Buy
456,789
+3,057
+0.7% +$322K 0.01% 660
2024
Q4 		$57.3M Buy
453,732
+95,813
+27% +$11.7M 0.02% 533
2024
Q3 		$42.9M Buy
357,919
+24,963
+7% +$3.45M 0.02% 574
2024
Q2 		$51M Sell
332,956
-65,330
-16% -$8.39M 0.02% 519
2024
Q1 		$46.4M Sell
398,286
-1,081
-0.3% -$132K 0.02% 537
2023
Q4 		$47.8M Buy
399,367
+91,880
+30% +$8.81M 0.02% 538
2023
Q3 		$36.3M Buy
307,487
+2,036
+0.7% +$230K 0.02% 575
2023
Q2 		$34.7M Buy
305,451
+92,319
+43% +$11.9M 0.02% 594
2023
Q1 		$29.3M Buy
213,132
+187,369
+727% +$24.3M 0.02% 632
2022
Q4 		$3.09M Buy
25,763
+23,359
+972% +$2.71M ﹤0.01% 1111
2022
Q3 		$266K Hold
2,404
– – ﹤0.01% 1424
2022
Q2 		$198K Hold
2,404
– – ﹤0.01% 1364
2022
Q1 		$213K Hold
2,404
– – ﹤0.01% 1381
2021
Q4 		$174K Hold
2,404
– – ﹤0.01% 1498
2021
Q3 		$222K Sell
2,404
-14,671
-86% -$1.13M ﹤0.01% 1431
2021
Q2 		$1.33M Buy
+17,075
New +$1.29M ﹤0.01% 1196

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Amundi's SRPT Position: Q2 2026 in Review

Amundi opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 19,456 shares worth $350K. The stake represents ﹤0.01% of the portfolio and ranks #1792 among its holdings. This is a return to the name: Amundi previously reported a position in SRPT as recently as Q4 2025.

Amundi first reported a position in SRPT in Q2 2021 and has held it in 20 quarters since. The position peaked at $57.3M in Q4 2024. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Amundi held 19,456 shares of Sarepta Therapeutics worth $350K as of Q2 2026.
  • Sarepta Therapeutics was a new Amundi position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1792 holding.
  • Amundi first reported a position in Sarepta Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Amundi's Sarepta Therapeutics position peaked at $57.3M in Q4 2024.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.